ABI
TBPH icon

Adamant Biomedical Investments’s Theravance Biopharma TBPH Stock Holding History

Adamant Biomedical Investments’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$171K Hold
11,428
– – 0.04% 97
2014
Q3 		$263K Buy
+11,428
New +$332K 0.07% 92

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adamant Biomedical Investments's TBPH Position: Q4 2014 in Review

Adamant Biomedical Investments held its Theravance Biopharma (TBPH) position steady in Q4 2014 at 11,428 shares worth $171K. The position accounts for 0.04% of the portfolio, ranked #97.

Adamant Biomedical Investments first reported a position in TBPH in Q3 2014 and has held it in 2 quarters since. The position peaked at $263K in Q3 2014. 94 funds tracked by Wall St. Rank hold TBPH as of Q4 2014.

  • Adamant Biomedical Investments held 11,428 shares of Theravance Biopharma worth $171K as of Q4 2014.
  • Adamant Biomedical Investments left its Theravance Biopharma share count unchanged in Q4 2014.
  • Theravance Biopharma made up 0.04% of Adamant Biomedical Investments's portfolio in Q4 2014, its #97 holding.
  • Adamant Biomedical Investments first reported a position in Theravance Biopharma in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Theravance Biopharma position peaked at $263K in Q3 2014.
  • 94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.